AUTHORS
Nora Balas, MSPH, PhD, Yanjun Chen2, Qingrui Meng3, Lindsey Hageman, MPH4, Wendy Landier, PhD5, Joshua Richman, MD, PhD6, Alysia Bosworth, BA7, F. Lennie Wong, PhD8, Ravi Bhatia, MD9, Daniel Weisdorf, MD10, Saro H Armenian, MD, MPH11, Smita Bhatia, MD, MPH12
AFFILIATIONS
1 University of Alabama at Birmingham, Birmingham, Alabama, United States
2 University of Alabama at Birmingham, Birmingham, Alabama, United States
3 University of Alabama at Birmingham, Birmingham, Alabama, United States
4 University of Alabama at Birmingham, Birmingham, Alabama, United States
5 University of Alabama at Birmingham, Birmingham, Alabama, United States
6 University of Alabama at Birmingham, Birmingham, Alabama, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 University of Alabama at Birmingham, Birmingham, Alabama, United States
10 University of Minnesota, Minneapolis, Minnesota, United States
11 City of Hope, Duarte, California, United States
12 University of Alabama at Birmingham, Birmingham, Alabama, United States
ABSTRACT
Introduction: Blood or marrow transplant (BMT) survivors are at increased risk for developing subsequent neoplasms (SNs; largely solid SNs), which remain a leading cause of late mortality. In the general population, cigarette smoking is a well-established risk factor for lung, oropharyngeal, esophageal, pancreatic, liver, gastric, colorectal, kidney, and bladder cancers. However, carcinogenesis after BMT occurs in a unique clinical setting characterized by intensive chemotherapy, total body irradiation (TBI), prolonged immunosuppression, and chronic graft-versus-host disease (cGvHD), all of which may alter smoking-related cancer susceptibility – but this question remains unstudied. The objectives of this study were to evaluate the risk of developing smoking-related SNs after allogeneic BMT and to identify demographic, clinical/therapeutic, and smoking-related risk factors associated with development of these SNs by leveraging the BMT Survivor Study (BMTSS).
Methods: BMTSS is a retrospective cohort study of individuals who were treated with BMT from 1974 to 2014 at three centers and survived ≥2y, regardless of vital status after cohort entry. Smoking-related SNs were evaluated using two approaches: 1) examining the magnitude of risk of developing smoking-related SNs in the entire cohort of allogeneic BMT recipients (n=3,956); and 2) examining the association between smoking and SNs in a subgroup who completed the BMTSS survey at age ≥18y and provided self-reported smoking history (n=2,284; 58% of entire cohort). Study participants were classified as never smokers (<100 cigarettes during their lifetime) and ever smokers (≥100 cigarettes); smoking duration was classified as <10y or ≥10y. Fine-Gray proportional sub-distribution hazard models were used to determine the hazard of smoking-related SNs (lung, oropharyngeal, esophageal, gastric, colorectal, pancreatic, liver, kidney, and bladder cancer), treating non-smoking SNs death as competing risks. Time at risk started at 2y after BMT and ended at the development of a smoking-related SNs, non-smoking related death (competing risk), or the last available survey date. Standardized incidence ratios (SIRs) quantified the excess risk of smoking-related SNs among BMT recipients when compared with the general population.
Results: In the entire cohort, the median age at BMT was 37.7y, 58.2% were male, 71.7% were non-Hispanic White, 55.8% developed cGvHD, 7.8% received pre-BMT radiation, and 63.5% received TBI. Over a median follow-up of 7.7y, 258 BMT survivors developed 270 smoking-related SNs (median latency to the first smoking-related SN: 12.8y). The 30y cumulative incidence was 14% (95%CI=12.2–15.5). Compared with the general population, BMT survivors had significantly increased risk of esophageal (SIR=19.2), liver (SIR=11.5), oropharyngeal (SIR=10.7), pancreatic (SIR=7.7), gastric (SIR=5.1), lung (SIR=4.2), kidney (SIR=2.9), colorectal (SIR=2.7), bladder (SIR=1.9) cancers, (all P<0.03). Multivariable analyses identified older age at BMT (per-year-increase in age: asHR=1.02, 95%CI=1.02-1.03), male sex (asHR=1.4, 95%CI=1.1-1.8), pre-BMT radiation (asHR=1.6, 95%CI=1.1-2.3), and cGvHD (asHR=1.3, 95%CI=1.0-1.7) as independent risk factors. In the subgroup cohort, 39.1% were ever smokers, of whom 72.2% had smoked for ≥10y. Over a median follow-up of 9.9y, 170 survivors developed 179 smoking-related SNs. The 30y cumulative incidence increased from 16.5% among never smokers to 21% among those who smoked for <10y and 34% among those who smoked for ≥10y. Multivariable analysis demonstrated a dose-response relationship between smoking duration and smoking-related SN risk (<10y: asHR=1.7, 95%CI=1.1–2.8; ≥10y: asHR=2.1, 95%CI=1.5–2.9; P-trend <0.0001; ref: never smokers). Based on the asHR, an estimated 53% of the SNs among survivors who smoked ≥10y were attributable to smoking compared with never smokers.
Conclusions: Smoking-related SN risk increased with longer smoking duration. These findings underscore the importance of smoking prevention/cessation efforts in allogeneic BMT survivors and support incorporation of smoking history into long-term survivorship care and cancer surveillance strategies for this high-risk population.
DISCLOSURES
Nora Balas, MSPH, PhD: No relevant conflicts of interest to declare.